Razpipadon

Razpipadon
Clinical data
Other names	CVL-871; PF-06669571; PW-0464
Routes of; administration	Oral administration
Drug class	Dopamine receptor agonist
Identifiers
	IUPAC name 6-[4-[3-(difluoromethoxy)pyridin-2-yl]oxy-2-methylphenyl]-1,5-dimethylpyrimidine-2,4-dione;
CAS Number	1643489-35-3;
PubChem CID	86764103;
ChemSpider	58945356;
UNII	6X6XF88J2M;
ChEMBL	ChEMBL3697578;
Chemical and physical data
Formula	C19H17F2N3O4
Molar mass	389.359 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=C(C=CC(=C1)OC2=C(C=CC=N2)OC(F)F)C3=C(C(=O)NC(=O)N3C)C;
	InChI InChI=1S/C19H17F2N3O4/c1-10-9-12(27-17-14(28-18(20)21)5-4-8-22-17)6-7-13(10)15-11(2)16(25)23-19(26)24(15)3/h4-9,18H,1-3H3,(H,23,25,26); Key:ZXIPVZWZRQCIRW-UHFFFAOYSA-N;

Razpipadon (developmental codes CVL-871, PF-06669571, and PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy.^[1]^[2]^[3]^[4] It is taken via oral administration.^[1]

Razpipadon acts as a selective partial agonist of the dopamine D₁ and D₅ receptors.^[1]^[2]^[5] The drug has been found to increase willingness to exert effort for rewards in humans and hence appears to show pro-motivational effects.^[6]^[7]

The drug was originated by Pfizer and is under development by Cerevel Therapeutics.^[1] As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy.^[1]

References

^ ^a ^b ^c ^d ^e "CVL 871 - AdisInsight".
^ ^a ^b Hatzipantelis CJ, Langiu M, Vandekolk TH, Pierce TL, Nithianantharajah J, Stewart GD, Langmead CJ (December 2020). "Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia". ACS Pharmacol Transl Sci. 3 (6): 1042–1062. doi:10.1021/acsptsci.0c00117. PMC 7737210. PMID 33344888.
^ Wang HJ, Chinna-Meyyappan A, Feldman OJ, Lanctôt KL (June 2024). "Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease". Expert Opin Emerg Drugs: 1–15. doi:10.1080/14728214.2024.2363215. PMID 38822731.
^ Dolphin H, Dyer AH, McHale C, O'Dowd S, Kennelly SP (July 2023). "An Update on Apathy in Alzheimer's Disease". Geriatrics (Basel). 8 (4): 75. doi:10.3390/geriatrics8040075. PMC 10366907. PMID 37489323.
^ "CVL-871 - Cerevel Therapeutics". 2 January 2020.
^ Webber HE, Lopez-Gamundi P, Stamatovich SN, de Wit H, Wardle MC (January 2021). "Using pharmacological manipulations to study the role of dopamine in human reward functioning: A review of studies in healthy adults". Neurosci Biobehav Rev. 120: 123–158. doi:10.1016/j.neubiorev.2020.11.004. PMC 7855845. PMID 33202256. Similarly, augmenting DA using a D1 agonist (PF-06412562; 6mg, 15mg, 30mg) increased willingness to exert physical effort for reward (Soutschek et al., 2020).
^ Soutschek A, Gvozdanovic G, Kozak R, Duvvuri S, de Martinis N, Harel B, Gray DL, Fehr E, Jetter A, Tobler PN (April 2020). "Dopaminergic D1 Receptor Stimulation Affects Effort and Risk Preferences". Biol Psychiatry. 87 (7): 678–685. doi:10.1016/j.biopsych.2019.09.002. PMID 31668477.

External links

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[AdisInsight-1] "CVL 871 - AdisInsight".

[HatzipantelisLangiuVandekolk2020-2] Hatzipantelis CJ, Langiu M, Vandekolk TH, Pierce TL, Nithianantharajah J, Stewart GD, Langmead CJ (December 2020). "Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia". ACS Pharmacol Transl Sci. 3 (6): 1042–1062. doi:10.1021/acsptsci.0c00117. PMC 7737210. PMID 33344888.

[WangChinna-MeyyappanFeldman2024-3] Wang HJ, Chinna-Meyyappan A, Feldman OJ, Lanctôt KL (June 2024). "Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease". Expert Opin Emerg Drugs: 1–15. doi:10.1080/14728214.2024.2363215. PMID 38822731.

[DolphinDyerMcHale2023-4] Dolphin H, Dyer AH, McHale C, O'Dowd S, Kennelly SP (July 2023). "An Update on Apathy in Alzheimer's Disease". Geriatrics (Basel). 8 (4): 75. doi:10.3390/geriatrics8040075. PMC 10366907. PMID 37489323.

[Cerevel-5] "CVL-871 - Cerevel Therapeutics". 2 January 2020.

[WebberLopez-GamundiStamatovich2021-6] Webber HE, Lopez-Gamundi P, Stamatovich SN, de Wit H, Wardle MC (January 2021). "Using pharmacological manipulations to study the role of dopamine in human reward functioning: A review of studies in healthy adults". Neurosci Biobehav Rev. 120: 123–158. doi:10.1016/j.neubiorev.2020.11.004. PMC 7855845. PMID 33202256. Similarly, augmenting DA using a D1 agonist (PF-06412562; 6mg, 15mg, 30mg) increased willingness to exert physical effort for reward (Soutschek et al., 2020).

[SoutschekGvozdanovicKozak2020-7] Soutschek A, Gvozdanovic G, Kozak R, Duvvuri S, de Martinis N, Harel B, Gray DL, Fehr E, Jetter A, Tobler PN (April 2020). "Dopaminergic D1 Receptor Stimulation Affects Effort and Risk Preferences". Biol Psychiatry. 87 (7): 678–685. doi:10.1016/j.biopsych.2019.09.002. PMID 31668477.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

See also

References

External links